期刊文献+

活络消痛汤联合美托洛尔对不稳定性心绞痛的治疗效果

下载PDF
导出
摘要 目的探讨活络消痛汤联合美托洛尔对不稳定性心绞痛的治疗效果。方法选择2018年1月至2019年9月中牟县第二人民医院收治的85例不稳定性心绞痛患者,采用抽签法将患者分为两组,对照组43例,观察组42例。对照组患者在常规治疗基础上口服美托洛尔,观察组在对照组治疗的基础上加用活络消痛汤,两组患者均连续治疗2个月。对两组患者治疗后心绞痛发作频率、持续时间进行比较,测定并比较治疗后两组患者血脂和C反应蛋白(CRP)水平。结果观察组总有效率为95.24%,高于对照组的72.09%,差异有统计学意义(P<0.05)。两组患者治疗后中医证候积分均低于治疗前,观察组中医证候积分低于对照组,差异有统计学意义(均P<0.05)。与对照组比较,观察组患者心绞痛发作频率下降,心绞痛持续时间缩短,血脂和CRP水平下降,差异有统计学意义(均P<0.05)。结论活络消痛汤联合美托洛尔治疗不稳定性心绞痛可有效降低患者心绞痛发作频率,缩短心绞痛持续时间,改善患者血脂及炎症反应水平,具有较好的治疗效果。
作者 吴小强
出处 《河南医学研究》 CAS 2020年第20期3789-3791,共3页 Henan Medical Research
  • 相关文献

参考文献4

二级参考文献33

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
  • 9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
  • 10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.

共引文献2180

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部